ended5월 12일· 1 sources
Moderna Leverages mRNA Success to Combat High-Fatality Hantavirus
Moderna, '치사율 40%' 한타바이러스 정조준... mRNA 백신 개발 가속
Why it matters
Moderna's collaboration with South Korea's VIC-K signals a strategic shift to apply proven mRNA platforms to neglected high-mortality pathogens. This move underscores a growing industry trend of proactive pandemic preparedness, targeting viruses with fatality rates reaching 40%.
1
Sources
+0
24h
—
Growth
9d
Active
ModernamRNA vaccineHantavirusVIC-KAndean hantavirus